These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33146913)

  • 41. Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
    Lotan Y; Inman BA; Davis LG; Kassouf W; Messing E; Daneshmand S; Canter D; Marble HT; Joseph AM; Jewell S; Boorjian SA
    J Urol; 2019 Nov; 202(5):920-926. PubMed ID: 31120373
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer.
    Sanchez A; Wszolek MF; Niemierko A; Clayman RH; Drumm M; Rodríguez D; Feldman AS; Dahl DM; Heney NM; Shipley WU; Zietman AL; Efstathiou JA
    J Urol; 2018 Feb; 199(2):407-415. PubMed ID: 28870862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
    Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
    Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting disease outcome of non-invasive transitional cell carcinoma of the urinary bladder using an artificial neural network model: results of patient follow-up for 15 years or longer.
    Fujikawa K; Matsui Y; Kobayashi T; Miura K; Oka H; Fukuzawa S; Sasaki M; Takeuchi H; Okabe T
    Int J Urol; 2003 Mar; 10(3):149-52. PubMed ID: 12622711
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
    Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dynamic Prognostication Using Conditional Recurrence and Progression Estimates for Patients with Nonmuscle Invasive Bladder Cancer.
    Leitner CV; Ederer IA; de Martino M; Hofbauer SL; Lucca I; Mbeutcha A; Mathieu R; Haitel A; Susani M; Shariat SF; Klatte T
    J Urol; 2016 Jul; 196(1):46-51. PubMed ID: 26835832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD; Sosa RE; Vaughan ED; Scherr DS
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bladder cancer mortality after a diagnosis of nonmuscle-invasive bladder carcinoma.
    Abdel-Rahman O
    Future Oncol; 2019 Jul; 15(19):2267-2275. PubMed ID: 31237444
    [No Abstract]   [Full Text] [Related]  

  • 51. Risk Factors Predictive of Recurrence and Progression for Patients Who Suffered Initial Recurrence After Transurethral Resection of Stage pT1 Bladder Tumor in Chinese Population: A Retrospective Study.
    Shen Z; Xie L; Chen T; Tian D; Liu X; Xu H; Zhang Y; Wu Z; Sha N; Xing C; Ding N; Hu H; Wu C
    Medicine (Baltimore); 2016 Feb; 95(5):e2625. PubMed ID: 26844474
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models.
    Xu T; Zhu Z; Zhang X; Wang X; Zhong S; Zhang M; Shen Z
    Urology; 2013 Aug; 82(2):387-93. PubMed ID: 23759377
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
    Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
    PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute.
    Miyake M; Gotoh D; Shimada K; Tatsumi Y; Nakai Y; Anai S; Torimoto K; Aoki K; Tanaka N; Konishi N; Fujimoto K
    Int J Urol; 2015 Jun; 22(6):541-7. PubMed ID: 25857336
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
    Ferro M; Vartolomei MD; Cantiello F; Lucarelli G; Di Stasi SM; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdonà S; Borghesi M; Schiavina R; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Verze P; Battaglia M; Serretta V; Russo GI; Morgia G; Musi G; de Cobelli O; Mirone V; Shariat SF
    Urol Int; 2018; 101(1):7-15. PubMed ID: 29975950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Guérin immunotherapy.
    Mano R; Zilber S; Di Natale RG; Kedar D; Lifshitz DA; Yossepowitch O; Baniel J; Margel D
    Urol Oncol; 2018 Dec; 36(12):531.e9-531.e17. PubMed ID: 30337218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urinary pH and the risk of recurrence in patients with non-muscle invasive bladder cancer.
    Stone BV; Ayangbesan A; Taylor BL; Golombos DM; Lewicki P; Al Hussein Al Awamlh B; O'Malley P; Kaplan SA; Scherr DS; Chughtai B
    Can J Urol; 2018 Aug; 25(4):9407-9412. PubMed ID: 30125520
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles.
    Birkhahn M; Mitra AP; Williams AJ; Lam G; Ye W; Datar RH; Balic M; Groshen S; Steven KE; Cote RJ
    Eur Urol; 2010 Jan; 57(1):12-20. PubMed ID: 19762144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.
    Kwak C; Ku JH; Park JY; Lee E; Lee SE; Lee C
    J Urol; 2004 Jan; 171(1):149-52. PubMed ID: 14665864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.